Literature DB >> 12020498

Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model.

Nicholas N Kipshidze1, Han Soo Kim, Patrick Iversen, Hamid A Yazdi, Balram Bhargava, Gishel New, Roxana Mehran, Fermin Tio, Christian Haudenschild, George Dangas, Gregg W Stone, Sriram Iyer, Gary S Roubin, Martin B Leon, Jeffrey W Moses.   

Abstract

OBJECTIVES: We evaluated the long-term influence of intramural delivery of advanced c-myc neutrally charged antisense oligonucleotides (Resten-NG) on neointimal hyperplasia after stenting in a pig model.
BACKGROUND: Neointimal hyperplasia after percutaneous coronary interventions is one of the key components of the restenotic process. The c-myc is a critical cell division cycle protein involved in the formation of neointima.
METHODS: In short-term experiments, different doses (from 500 microg to 5 mg) of Resten-NG or saline were delivered to the stent implantation site with an infiltrator delivery system (Interventional Technologies, San Diego, California). Animals were euthanized at 2, 6 and 18 h after interventions, and excised vessels were analyzed for c-myc expression by Western blot. In long-term experiments, either saline or a dose of 1, 5 or 10 mg of Resten-NG was delivered in the same fashion, and animals were euthanized at 28 days after the intervention.
RESULTS: Western blot analysis demonstrated inhibition of c-myc expression and was dose dependent. Morphometry showed that the intimal area was 3.88 +/- 1.04 mm(2) in the control. There was statistically significant reduction of intimal areas in the 5 and 10 mg groups (2.01 +/- 0.66 and 1.95 +/- 0.91, respectively, p < 0.001) but no significant reduction in the 1 mg group (2.81 +/- 0.56, p > 0.5) in comparison with control.
CONCLUSIONS: This study demonstrated that intramural delivery of advanced c-myc neutrally charged antisense morpholino compound completely inhibits c-myc expression and dramatically reduces neointimal formation in a dose dependent fashion in a porcine coronary stent restenosis model, while allowing for complete vascular healing.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12020498     DOI: 10.1016/s0735-1097(02)01830-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  9 in total

Review 1.  The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.

Authors:  Thierry Charron; Nafiseh Nili; Bradley H Strauss
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

Review 2.  Delivery of large biopharmaceuticals from cardiovascular stents: a review.

Authors:  Hironobu Takahashi; Didier Letourneur; David W Grainger
Journal:  Biomacromolecules       Date:  2007-10-12       Impact factor: 6.988

3.  Aldose reductase regulates vascular smooth muscle cell proliferation by modulating G1/S phase transition of cell cycle.

Authors:  Ravinder Tammali; Ashish Saxena; Satish K Srivastava; Kota V Ramana
Journal:  Endocrinology       Date:  2010-03-22       Impact factor: 4.736

4.  Antisense morpholino-oligomers directed against the 5' end of the genome inhibit coronavirus proliferation and growth.

Authors:  Benjamin W Neuman; David A Stein; Andrew D Kroeker; Amy D Paulino; Hong M Moulton; Patrick L Iversen; Michael J Buchmeier
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

Review 5.  [When are drug-eluting stents effective? A critical analysis of the presently available data].

Authors:  S Silber
Journal:  Z Kardiol       Date:  2004-09

6.  Inhibition of infectious haematopoietic necrosis virus in cell cultures with peptide-conjugated morpholino oligomers.

Authors:  M Alonso; D A Stein; E Thomann; H M Moulton; J C Leong; P Iversen; D V Mourich
Journal:  J Fish Dis       Date:  2005-07       Impact factor: 2.767

7.  Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections.

Authors:  Patrick L Iversen; Travis K Warren; Jay B Wells; Nicole L Garza; Dan V Mourich; Lisa S Welch; Rekha G Panchal; Sina Bavari
Journal:  Viruses       Date:  2012-11-06       Impact factor: 5.048

Review 8.  The use of microbubbles to target drug delivery.

Authors:  Jeane M Tsutsui; Feng Xie; Richard Thomas Porter
Journal:  Cardiovasc Ultrasound       Date:  2004-11-16       Impact factor: 2.062

Review 9.  The potential of antisense oligonucleotide therapies for inherited childhood lung diseases.

Authors:  Kelly M Martinovich; Nicole C Shaw; Anthony Kicic; André Schultz; Sue Fletcher; Steve D Wilton; Stephen M Stick
Journal:  Mol Cell Pediatr       Date:  2018-02-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.